• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/1/21 4:33:08 PM ET
    $AHAC
    Business Services
    Finance
    Get the next $AHAC alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No. __N/A__)*

     

    Alpha Healthcare Acquisition Corp.

     

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    020751103

     

    (CUSIP Number)

     

    February 24, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)
         
      [X] Rule 13d-1(c)
         
      [  ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       
     

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Parian Global Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      844,734 (See Item 4 below)  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      844,734 (See Item 4 below)  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      844,734 (See Item 4 below)  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        [  ]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.16%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA  

     

       
     

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Parian Global Master Fund LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      648,844 (See Item 4 below)  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      648,844 (See Item 4 below)  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      648,844 (See Item 4 below)  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        [  ]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.27%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  

     

       
     

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      CCZG LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
         
    5. SOLE VOTING POWER  
         
    0  
         
    6. SHARED VOTING POWER  
         
      844,734 (See Item 4 below)  
         
    7. SOLE DISPOSITIVE POWER  
         
    0  
         
    8. SHARED DISPOSITIVE POWER  
         
      844,734 (See Item 4 below)  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      844,734 (See Item 4 below)  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        [  ]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.16%  
         
    12. TYPE OF REPORTING PERSON  
         
      (SEE INSTRUCTIONS)  
         
      HC  

     

       
     

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Zachary C. Miller  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  
        (a)  [  ]
      (b)  [  ]
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
         
    5. SOLE VOTING POWER  
         
    0   
         
    6. SHARED VOTING POWER  
         
      844,734 (See Item 4 below)  
         
    7. SOLE DISPOSITIVE POWER  
         
    0  
         
    8. SHARED DISPOSITIVE POWER  
         
      844,734 (See Item 4 below)  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      844,734 (See Item 4 below)  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        [  ]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.16%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      HC, IN  

     

       
     

     

    Item 1. (a). Name of Issuer:
         
        Alpha Healthcare Acquisition Corp.
         
         
      (b). Address of issuer’s principal executive offices:
         
        1177 Avenue of the Americas, 5th Floor
         
        New York, NY 10036
         
         
    Item 2. (a). Name of person filing:
         
        Parian Global Management LP
        Parian Global Master Fund LP
        CCZG LLC
        Zachary C. Miller
         
         
      (b). Address or principal business office or, if none, residence:
         
        c/o Parian Global Management LP
        One Grand Central Place
        60 E. 42nd St., Suite 850
         
        New York, NY 10165
         
         
      (c). Citizenship:
         
        Parian Global Management LP - Delaware
        Parian Global Master Fund LP – Cayman Islands
        CCZG LLC – Delaware
        Zachary C. Miller – United States
         
         
      (d). Title of class of securities:
         
        Class A Common Stock, par value $0.0001 per share
         
         
      (e). CUSIP No.:
         
        020751103
         

     

       
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
       
      N/A
           
    Item 4. Ownership.
      Shares reported herein are beneficially owned by Parian Global Management LP (“Parian”) in its capacity as investment manager to Parian Global Master Fund LP and one or more other private investment vehicles. CCZG LLC serves as general partner of Parian, and Mr. Miller is the managing member of CCZG LLC. Shares reported herein for CCZG LLC and Mr. Miller represent the above referenced shares reported with respect to Parian. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. The percentages reported herein are calculated based upon the statement in the Issuer’s Report on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on February 16, 2021, that there were 10,355,000 shares of Class A Common Stock of the Issuer outstanding as of February 16, 2021.
           
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
      (a) Amount beneficially owned:
           
          Parian Global Management LP – 844,734
          Parian Global Master Fund LP - 648,844
          CCZG LLC – 844,734
          Zachary C. Miller – 844,734
           
           
      (b) Percent of class:
         
          Parian Global Management LP – 8.16%
          Parian Global Master Fund LP – 6.27%
          CCZG LLC – 8.16%
          Zachary C. Miller – 8.16%
           
           
      (c)   Number of shares as to which the person has:

     

          (i) Sole power to vote or to direct the vote
             
            Parian Global Management LP – 0
            Parian Global Master Fund LP - 0
            CCZG LLC – 0
            Zachary C. Miller – 0
             
          (ii) Shared power to vote or to direct the vote
             
            Parian Global Management LP – 844,734
            Parian Global Master Fund LP - 648,844
            CCZG LLC – 844,734
            Zachary C. Miller – 844,734
             
          (iii) Sole power to dispose or to direct the disposition of
             
            Parian Global Management LP – 0
            Parian Global Master Fund LP - 0
            CCZG LLC – 0
            Zachary C. Miller – 0
             
          (iv) Shared power to dispose or to direct the disposition of
             
            Parian Global Management LP – 844,734
            Parian Global Master Fund LP - 648,844
            CCZG LLC – 844,734
            Zachary C. Miller – 844,734

     

       
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.
       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent
      Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

       
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: March 1, 2021    
        Parian Global Management LP
        By: CCZG LLC, its General partner
           
        By: /s/ Zachary C. Miller
          Zachary C. Miller, Managing Member
           
        Parian Global Master LP
        By: Parian Global Management LP, its Investment Manager
        By: CCZG LLC, the General Partner of the Investment Manager
           
        By: /s/ Zachary C. Miller
        Zachary C. Miller, Managing Member
           
        CCZG LLC
           
        By: /s/ Zachary C. Miller
          Managing Member
           
        Zachary C. Miller
           
        By: /s/ Zachary C. Miller
          Zachary C. Miller

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

       

     

    Get the next $AHAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHAC

    DatePrice TargetRatingAnalyst
    7/20/2021$18.00Buy
    Benchmark
    7/20/2021$18.00Buy
    The Benchmark Company
    More analyst ratings

    $AHAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Scheessele William John

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:51:53 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Binder Gordon M

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:43:59 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Brown Emery N.

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:42:44 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

    NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the

    8/24/21 12:58:48 PM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

    In addition to the Company's eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U

    8/19/21 7:30:00 AM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    $AHAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on Alpha Healthcare with a new price target

    Benchmark initiated coverage of Alpha Healthcare with a rating of Buy and set a new price target of $18.00

    7/20/21 7:58:11 AM ET
    $AHAC
    Business Services
    Finance

    The Benchmark Company initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $18.00

    7/20/21 7:16:19 AM ET
    $AHAC
    Business Services
    Finance

    Lake Street initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    Lake Street initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $20.00

    4/9/21 8:42:45 AM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    SEC Filings

    View All

    SEC Form S-1 filed by Alpha Healthcare Acquisition Corp.

    S-1 - Humacyte, Inc. (0001818382) (Filer)

    9/17/21 4:59:30 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Leadership Update

    8-K - Humacyte, Inc. (0001818382) (Filer)

    9/2/21 12:20:03 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - Humacyte, Inc. (0001818382) (Filer)

    8/27/21 9:01:49 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp.

    SC 13G - Humacyte, Inc. (0001818382) (Subject)

    9/8/21 4:22:18 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    9/2/21 6:04:40 AM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    8/27/21 9:14:01 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance